BMO Capital initiated coverage of Novartis with a Market Perform rating and $114 price target. Following the Sandoz spinoff, Novartis is well positioned for long-term growth, the analyst tells investors in a research note. However, despite the firm’s above-consensus sales growth through management’s mid-term guidance timeframe, its target price implies modest upside to current levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Erasca announces two CTCSAs with Novartis for trametinib
- Biotech Alert: Searches spiking for these stocks today
- MorphoSys tells Bloomberg STAT story ‘factually wrong’
- Novartis will ‘walk away from’ deal to buy MorphoSys, STAT’s Feuerstein says
- M & A News: Novartis (NYSE:NVS) to Acquire MorphoSys in $2.9B Deal
